The rare disease biotech will wind down the HyBryte program — its lead skin lymphoma drug — for about $70,000, narrow its pipeline to a single mid stage asset, and test the deal market as it weighs a possible merger or acquisition.
Soligenix is ending development of HyBryte, its lead treatment for cutaneous T-cell lymphoma, a rare skin lymphoma, after a confirmatory phase 3 study failed, and the small rare-disease biotech is now formally testing the deal market for a buyer or partner.
The board's decision, announced this week, closes a chapter that began in April when an independent data monitoring committee (DMC) recommended the company stop the trial after an interim review found it was unlikely to succeed, according to Fierce Biotech's Nick Paul Taylor, who reported the wind-down on June 15. The board reached its own conclusion late last week, judging the shutdown to be in the best interests of the business and shareholders, per the same Fierce Biotech story.
The cost of closing out the program is unusually small for a late-stage oncology collapse: roughly $70,000, most of it clinical close-out work. That figure underlines how little remained to salvage from a trial that was already running on borrowed regulatory time.
The failure trajectory was long. Soligenix had originally filed HyBryte, a synthetic form of hypericin applied to skin lesions and activated by fluorescent light, for approval after an earlier phase 3 study hit its primary endpoint. The FDA responded with a refusal-to-file letter asking for a second, confirmatory study. The 2025-started trial was meant to be that second study. When its interim look came back negative, the DMC recommended stopping it. The company told investors last month it was still assessing why the trial failed, and the board's late-June decision is the formal end of that review.
With the lead program gone, Soligenix is narrowing its pipeline to a single mid-stage asset: dusquetide, a synthetic innate-immune peptide with completed phase 2a data in Behçet's disease, a different rare inflammatory condition. The market is not yet rewarding that bet. Soligenix carries roughly $6 million in cash against a market capitalization near $6.4 million, and management has guided runway only into the second quarter, with no follow-on offering or partnership announced.
That mismatch is exactly why the company has now formally opened a strategic-alternatives review, corporate shorthand for testing a possible sale, merger, or partnership. A buyer picking up Soligenix would, in theory, get a publicly listed shell with one clinical-stage rare-disease asset, a small cash balance, and no live late-stage program to wind down. Whether anyone pays meaningful money for that is the open question.
For other micro-cap rare-disease biotechs watching the HyBryte arc, the lesson is partly mechanical. A failed second trial does not have to end the company. Soligenix is showing what a low-cost wind-down looks like, and what a residual pipeline plus an open M&A review can buy a board that moves early and decisively.
The next data point is timing. Strategic-alternatives reviews either produce a deal within a few quarters or quietly close with no transaction. Soligenix has not named a financial advisor, a buyer, or a target close date, and the review could end with no deal at all. The board's mid-June decision opened the window. Whether anyone walks through it is the part still to be written.